Komori
Management planning2158FRONTEO,Inc.Information and Communications, Services and Others

Execution of a term loan agreement and an overdraft agreement to accelerate growth in the life sciences AI business (AI drug discovery field)

The Company entered into borrowing facilities and loan agreements with 3 banks totaling ¥1,220 million to fund growth investments and working capital for its Life Sciences AI Business (AI drug discovery). The combined limits for overdrafts and special overdrafts are ¥920 million, while the term loan is ¥300 million.

Worth reading
11Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
1220
¥ million
Wording
Definitive
How definitive the wording is.

Items stated in the management plan

Publication date24 July 2026

This document does not state the plan name, plan period, or numerical targets.

Key initiatives
01R&D investment to advance solutions and analytical methodologies
02Strengthening the organizational structure, including the recruitment and development of specialized personnel
03Investments and working capital associated with promoting co-creation projects, PoCs and other initiatives
Items stated in the management plan
ItemDetails
Key initiativesR&D investment to advance solutions and analytical methodologies, Strengthening the organizational structure, including the recruitment and development of specialized personnel, Investments and working capital associated with promoting co-creation projects, PoCs and other initiatives
Publication date24 July 2026
Items this document does not state (23)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To transition the Life Sciences AI Business into a full-scale monetization phase and grow it as a core business, the Company will address increased funding needs associated with R&D investment, the recruitment and development of specialized personnel, and co-creation projects and PoCs, while strengthening the stability of its financial base and the flexibility and safety of its growth investments.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Execution of a term loan agreement and an overdraft agreement to accelerate growth in the life sciences AI business (AI drug discovery field) | FRONTEO,Inc. (2158) timely disclosure | Komori